00

Guangdong Zhongsheng Pharmaceutical Co LtdSHE 002317 Stock Report

Last reporting period 30 Sep, 2023

Updated 08 Nov, 2024

Last price

Market cap $B

1.347

Small

Exchange

XSHE - Shenzhen Stock Exchange

002317.SZ Stock Analysis

00

Avoid

Based on Eyestock quantitative analysis, 002317.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

33/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

36.1 %

Undervalued

Market cap $B

1.347

Dividend yield

1.39 %

Shares outstanding

808.88 B

Guangdong Zhongsheng Pharmaceutical Co., Ltd. engages in the manufacture, sale, research and development of medicine. The company is headquartered in Dongguan, Guangdong and currently employs 1,626 full-time employees. The company went IPO on 2009-12-11. is a China-based company principally engaged in the research, development, manufacture and distribution of medicines. The Company’s medicine products are categorized into Chinese patent medicines, chemical drugs, chemical bulk drugs and herbal decoction pieces, which include capsules for thrombus, pellets for upper respiratory tract diseases, granular for sunstroke, compound dexamethasone acetate creams and azelastine hydrochloride eye drops, among others. The firm distributes its products in domestic market.

View Section: Eyestock Rating